The symposium will be organised as a single-track scientific meeting and count with keynote & invited speakers, talks selected from abstracts and a poster session together with other networking and social activities. It will be held on the 11^th and 12^th of March, 2024 at the Main Auditorium of the Champalimaud Foundation in Lisbon, Portugal.

In November 2023, a meeting on malignant melanoma, entitled "Challenging Malignant Melanoma", was held at the Champalimaud Foundation. It was organised by the Dermatology Unit and aimed at doctors and researchers from various specialisations. The organisers consider it a success and intend to repeat this type of event to bring together clinical and scientific expertise.

Slated to begin recruiting patients in 2025, the PsyPal study represents a significant step in exploring innovative treatments for deep psychological and existential distress in those with advanced illnesses. The CF, alongside three other European clinical sites, will treat over one hundred patients, each site focusing on a different condition.

The ERC Proof of Concept Grant is awarded exclusively to Principal Investigators who have previously won an ERC grant. Its primary goal is to support the commercial and social innovation potential of ERC-funded research. “It takes courage and skill to take an idea from the lab into the world of business. The Proof of Concept grants announced today are designed to enable researchers to take this brave step and transform groundbreaking research into tangible innovations”, remarked Iliana Ivanova, European Commissioner for Innovation, Research, Culture, Education and Youth.

The objective of this partnership will be focused on research and improvement of medicine dedicated to the treatment of patients with pancreatic cancer.

This collaboration will reinforce scientific exchange between the two institutions and will be led by doctors and researchers from both institutions such as Carlos Carvalho and Sherman Moreira from the Champalimaud Foundation, and Gustavo Guimarães, Bendito Rossi and Fabio Kater from Beneficência Portuguesa de São Paulo.

The largest bottleneck medical research organisations at the forefront of technology face is access to useful data. These difficulties stem from strict policies that limit access to ML teams instead of allowing technology to enable and ensure responsible data use. Potential ML solutions are greatly stifled due to insufficient ability to access, standardise, and aggregate valuable data that continues to be siloed away. Yet, over the last years we have seen two general paradigms emerge to address important technical challenges.